Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

Abstract:

:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manifestations of the metabolic syndrome. In this group, the measured volume of the prostate was related consecutively to potential risk factors. The diagnoses atherosclerosis, non-insulin-dependent diabetes mellitus (NIDDM) and treated hypertension were obtained from the patient's medical history. Data on blood pressure, waist and hip measure, body height and weight were collected and body mass index (BMI) and waist/hip ratio (WHR) were calculated. Blood samples were drawn from fasting patients to determine insulin, cholesterol, triglycerides, HDL and LDL-cholesterol, uric acid and ALAT. The prostate gland volume was determined using ultrasound. Our results show that there was a larger prostate gland in men with NIDDM (P=0.0058), treated hypertension (P=0.0317), obesity (P<0.0001), low HDL-cholesterol levels (P=0.0132) and high insulin levels (P<0.0001) than in men without these conditions. The prostate gland volume correlated positively with the systolic blood pressure (r(s)=0.17; P=0.03), obesity (r(s)=0.34; P<0.0001) and fasting insulin (r(s)=0.38; P<0.0001) and negatively with HDL-cholesterol (r(s)=-0.22; P=0.009). On the basis of our findings, we concluded that NIDDM, treated hypertension, obesity, low HDL-cholesterol levels and high insulin levels constitute risk factors for the development of BPH. The results suggest that BPH is a facet of the metabolic syndrome and that BPH patients may share the same metabolic abnormality of a defective insulin-mediated glucose uptake and secondary hyperinsulinemia as patients with the metabolic syndrome. The findings generate a hypothesis of a causal relationship between high insulin levels and the development of BPH. In a clinical setting, the findings of the present report suggest that, in any patient presenting with BPH, the possible presence of NIDDM, hypertension, obesity, high insulin and low HDL-cholesterol levels should be considered. Conversely, in patients suffering from these conditions, the possibility of a clinically important BPH should be kept in mind.

authors

Hammarsten J,Högstedt B,Holthuis N,Mellström D

doi

10.1038/sj.pcan.4500221

subject

Has Abstract

pub_date

1998-03-01 00:00:00

pages

157-162

issue

3

eissn

1365-7852

issn

1476-5608

pii

4500221

journal_volume

1

pub_type

杂志文章
  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0224-4

    authors: Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期:2020-12-01 00:00:00

  • Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis.

    abstract:BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2016.29

    authors: Zhao Y,Lv JJ,Chen J,Jin XB,Wang MW,Su ZH,Wang LY,Zhang HY

    更新日期:2016-12-01 00:00:00

  • Gene delivery into prostate cancer cells by holmium laser application.

    abstract::New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500653

    authors: Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

    更新日期:2003-01-01 00:00:00

  • The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.

    abstract:BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2017.29

    authors: Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

    更新日期:2017-12-01 00:00:00

  • The management of locally advanced prostate cancer.

    abstract::The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prost...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500620

    authors: Valicenti RK

    更新日期:2002-01-01 00:00:00

  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

    abstract::We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2008.18

    authors: Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

    更新日期:2008-01-01 00:00:00

  • Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

    abstract::The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4501001

    authors: Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

    更新日期:2008-01-01 00:00:00

  • Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia.

    abstract::In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as wel...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500302

    authors: Lowe F

    更新日期:1999-05-01 00:00:00

  • Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.

    abstract:BACKGROUND:To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS:Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years). Patients with a c...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2015.33

    authors: Latifoltojar A,Dikaios N,Ridout A,Moore C,Illing R,Kirkham A,Taylor S,Halligan S,Atkinson D,Allen C,Emberton M,Punwani S

    更新日期:2015-12-01 00:00:00

  • The potential role of bisphosphonates in prostate cancer.

    abstract::Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500607

    authors: Oades GM,Coxon J,Colston KW

    更新日期:2002-01-01 00:00:00

  • Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.

    abstract:BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1038/pcan.2014.13

    authors: Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

    更新日期:2014-09-01 00:00:00

  • Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation.

    abstract::We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.55

    authors: Zeng X,Sikka SC,Huang L,Sun C,Xu C,Jia D,Abdel-Mageed AB,Pottle JE,Taylor JT,Li M

    更新日期:2010-06-01 00:00:00

  • Effects of soy phytoestrogens on the prostate.

    abstract::Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500953

    authors: Goetzl MA,Van Veldhuizen PJ,Thrasher JB

    更新日期:2007-01-01 00:00:00

  • High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.

    abstract:BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2013.33

    authors: Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

    更新日期:2013-12-01 00:00:00

  • Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

    abstract:BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/s41391-017-0030-9

    authors: Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

    更新日期:2018-06-01 00:00:00

  • Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up.

    abstract::The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.pcan.4500631

    authors: Dunsmuir WD,McFarlane JP,Tan A,Dowling C,Downie J,Kourambas J,Donnellan S,Redgrave N,Fletcher R,Frydenberg M,Love C

    更新日期:2003-01-01 00:00:00

  • Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.

    abstract:BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2016.38

    authors: Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

    更新日期:2016-12-01 00:00:00

  • TGFBR1*6A is not associated with prostate cancer in men of European ancestry.

    abstract::The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500765

    authors: Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

    更新日期:2005-01-01 00:00:00

  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.

    abstract:BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-019-0197-3

    authors: Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

    更新日期:2020-09-01 00:00:00

  • Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.

    abstract::The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2010.4

    authors: Gacci M,Corona G,Apolone G,Lanciotti M,Tosi N,Giancane S,Masieri L,Serni S,Maggi M,Carini M

    更新日期:2010-06-01 00:00:00

  • Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions.

    abstract:PURPOSES:To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. SCOPE:Only biopsied men (sextant) were included. A total of 1011 biopsy sessio...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500730

    authors: Lujan M,Paez A,Santonja C,Pascual T,Fernandez I,Berenguer A

    更新日期:2004-01-01 00:00:00

  • Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model.

    abstract:BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-00288-y

    authors: Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

    更新日期:2020-09-28 00:00:00

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.

    abstract:BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-019-0136-3

    authors: Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

    更新日期:2019-12-01 00:00:00

  • The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.

    abstract:INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500889

    authors: Kastner C,Armitage J,Kimble A,Rawal J,Carter PG,Venn S

    更新日期:2006-01-01 00:00:00

  • Androgen receptor antigen density and S-phase fraction in prostate cancer: a pilot study.

    abstract:PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500672

    authors: Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

    更新日期:2003-01-01 00:00:00

  • The role of external radiotherapy in patients treated with permanent prostate brachytherapy.

    abstract::To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500552

    authors: Potters L,Fearn P,Kattan M

    更新日期:2002-01-01 00:00:00

  • 'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy.

    abstract::'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/sj.pcan.4500963

    authors: Johnstone PA,Rossi PJ,Jani AB,Master V

    更新日期:2007-01-01 00:00:00

  • Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men.

    abstract::We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500738

    authors: Veltri RW,Park J,Miller MC,Marks L,Kojima M,van Rootselaar C,Khan MA,Partin AW

    更新日期:2004-01-01 00:00:00

  • Histopathological findings after radiofrequency (RITA) treatment for prostate cancer.

    abstract::Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500877

    authors: Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

    更新日期:2006-01-01 00:00:00

  • Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

    abstract:BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/pcan.2012.12

    authors: Tunn UW,Canepa G,Kochanowsky A,Kienle E

    更新日期:2012-09-01 00:00:00